1737 — Taiyen Biotech Co Cashflow Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesConservativeSmall CapNeutral

Annual cashflow statement for Taiyen Biotech Co, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	464	510	531	329	433
Depreciation
Amortisation
Non-Cash Items	-12.4	0.594	-6.2	47	39.3
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-298	-100	-139	-120	-30.8
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	339	600	581	455	660
Capital Expenditures	-265	-389	-246	-342	-308
Purchase of Fixed Assets
Other Investing Cash Flow Items	12.3	37.4	16.5	2.35	19.8
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Change in Net Intangibles
Other Investing Cash Flow
Cash from Investing Activities	-252	-351	-230	-339	-288
Financing Cash Flow Items	146	3.98	9.97	20.6	1.12
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Debt
Cash from Financing Activities	-181	-28.4	-548	-199	-267
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-93.5	220	-197	-84.4	107